Project Description

Aruna Bio
2nd Generation Technology And a New Research Partner!

Date & Time:

February 25, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Aruna Bio has signed research agreement with a third major pharmaceutical company to explore the use of their neural exosome platform to deliver their specialized therapeutic to the brain and central nervous system.

Aruna Bio’s innovative payload delivery system protects therapeutics as they cross the Blood/Brain Barrier. Their ongoing research has also significantly improved the efficiency and durability of their platform, delivering a higher percentage of its payload with a greater degree of accuracy.

Aruna Bio will transform treatment for over 12 million patients via:
  • Partnerships with three global pharmaceutical leaders
  • A dedicated manufacturing facility to ensure availability
  • A pipeline delivery applications to treat Alzheimer’s, Parkinson’s Disease, Multiple Sclerosis and other neurodegenerative diseases
Please join us to hear from CEO, Mark Sirgo and Co-founder, Steven Stice, PhD to learn about their partnerships and the advances they’re making in delivering highly toxic therapeutics safely to the brain and central nervous system.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.